Evotec and Almirall fast-track dermatology candidate to preclinical development

Evotec (NASDAQ:EVO) today announced a significant milestone in its multi-target dermatology collaboration with Almirall, nominating a small-molecule preclinical development candidate (PDC) for the treatment of immune-mediated inflammatory skin diseases.

The joint research team achieved the transition from initial lead compounds to a nominated PDC in approximately two years.

This accelerated timeline was made possible by leveraging Evotec's proprietary artificial intelligence and machine learning (AI/ML) enhanced discovery and preclinical platforms.

The program integrates Evotec’s end-to-end drug discovery capabilities with Almirall’s deep therapeutic expertise in medical dermatology.

Following the nomination, the program will now transition into Investigational New Drug (IND) enabling studies.

Evotec will utilize its INDiGO platform—an integrated, data-driven solution designed to reduce time and cost by managing the transition from PDC to IND filing under a single roof.

This phase is critical for establishing the safety and efficacy profiles required for the candidate to enter human clinical trials.

The collaboration, which began with the goal of identifying first-in-class treatments for chronic skin conditions, continues to focus on addressing high unmet medical needs.

The nomination of this PDC triggers an undisclosed milestone payment to Evotec, further validating the efficiency of its collaborative R&D model.